SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study.

6569Background: Sitravatinib (receptor TKI against TYRO3, AXL, MERTK and VEGF family of receptors) is predicted to increase M1-type tumor-associated macrophages (TAMs) and decrease MDSCs in the tum...